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Objectives. We sought to assess the prognostic implications of
the evolution of restrictive left ventricular filling pattern (RFP) in
dilated cardiomyopathy (DCM).
Background. Previous work has demonstrated that a RFP in
DCM is associated with a poor prognosis. Few data are available
on the prognostic implications of the evolution of this pattern.
Methods. The evolution of left ventricular filling was studied by
Doppler echocardiography in 110 patients with DCM. According
to the left ventricular filling pattern at presentation and after 3
months of treatment, the patients were classified into three
groups: Group 1A (n 5 24) had persistent restrictive filling;
Group 1B (n 5 29) had reversible restrictive filling; and Group 2
(n 5 57) had nonrestrictive filling.
Results. During follow-up (41 6 20 months), mortality plus
heart transplantation was significantly higher in Group 1A than
in Groups 1B and 2 (p < 0.0001). On multivariate analysis, the
model incorporating E wave deceleration time at 3 months was
more powerful at predicting mortality with respect to this variable
at baseline (p 5 0.0039). Clinical improvement at 1 and 2 years
was significantly more frequent in Groups 1B and 2 than in Group
1A (p < 0.0001 at 2 years).
Conclusions. In patients with DCM, the persistence of restric-
tive filling at 3 months is associated with a high mortality and
transplantation rate. The patients with reversible restrictive fill-
ing have a high probability of improvement and excellent survival.
Doppler echocardiographic reevaluation of these patients after 3
months of therapy gives additional prognostic information with
respect to the initial study.
(J Am Coll Cardiol 1997;29:604–12)
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A wide spectrum of left ventricular (LV) filling patterns was
found during Doppler echocardiography in dilated cardiomy-
opathy (DCM) (1–9). Previous works (3–12) demonstrated
that in DCM a “restrictive” (LV) filling pattern (RFP), char-
acterized on Doppler echocardiography by a shortened trans-
mitral E wave deceleration time (EDT), is associated with a
more severe clinical and hemodynamic status and with in-
creased mortality and heart transplantation rates. However,
few data are presently available on the RFP changes during the
course of the disease (7,9,13,14) and on their clinical and
prognostic implications. Therefore, the objectives of this study
were to assess the evolution of the LV filling pattern in DCM
and to evaluate its clinical and prognostic implications in
comparison with the initial evaluation.
Methods
Study patients. A consecutive series of 110 patients (89
men, mean age 40 6 14 years) with DCM were evaluated by
Doppler echocardiography at presentation and during follow-
up. The diagnosis of DCM was made according to usual
criteria (15), in the presence of a depressed LV ejection
fraction (EF) (,50% by both echocardiography and angiogra-
phy) and in the absence of significant coronary artery disease
and other specific heart muscle diseases. In addition, an
adequate transmitral Doppler curve was required.
Clinical and hemodynamic evaluation. The study patients
were evaluated at clinical presentation, after 3 6 2 months of
tailored medical treatment and at long-term follow-up (1
year 6 3 months and 2 years 6 6 months after presentation).
Clinical data included New York Heart Association func-
tional class, third heart sound and cardiothoracic ratio on chest
X-ray film. Ventricular arrhythmias were evaluated by Holter
electrocardiographic monitoring. Exercise tolerance was eval-
uated using a symptom-limited bicycle ergometer test in the
upright position, with increments of 10 W/min.
Hemodynamic study, including coronary angiography and
endomyocardial biopsy, was performed in all patients at diag-
nosis. Significant coronary stenosis (.50%) and myocarditis
were excluded.
At the baseline evaluation, 76 patients (69%) were treated
with angiotensin-converting enzyme (ACE) inhibitors (capto-
pril or enalapril), 103 (94%) with digoxin, 76 (69%) with
diuretic agents, 20 (18%) with amiodarone and 6 (5%) with
beta-adrenergic blocking agents (metoprolol).
From the Departments of Cardiology and Economics and Statistics, Univer-
sity of Trieste, Italy. This study was presented in part at the 68th Scientific
Sessions of the American Heart Association, Anaheim, California, November
1995.
Manuscript received June 28, 1996; revised manuscript received October 15,
1996, accepted November 12, 1996.
Address for correspondence: Dr. Bruno Pinamonti, Department of Cardiol-
ogy, Ospedale Maggiore, Piazza Ospedale 1, 34129 Trieste, Italy.
JACC Vol. 29, No. 3
March 1, 1997:604–12
604
q1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(96)00539-6
Echocardiographic study. Conventional M-mode, two-
dimensional and Doppler variables (5) were measured in all
patients at presentation and at 3 6 2, 12 6 3 and 24 6 6
months of follow-up. Left ventricular volumes and EF were
calculated from the apical four-chamber view using the ellip-
soid, single-plane formula. Right ventricular areas and the
shortening fraction of areas, as well as the end-systolic left
atrial area, were also measured with the same approach.
Mitral regurgitation (MR) was semiquantitatively graded
from 11 to 41 considering the regurgitant jet area at color
Doppler imaging (5). Mitral regurgitation graded .11 was
considered significant.
The transmitral flow velocity curve was obtained by pulsed
Doppler imaging, positioning the sample volume between the
tips of the mitral leaflets. E wave and A wave peak velocities,
EDT and the ratio of early transmitral flow velocity to atrial
flow velocity (E/A ratio) were measured, as described previ-
ously (1,5).
According to our previous report (5), RFP was diagnosed
when the EDT was,115 ms. All measurements were obtained
from the mean of 3 beats for the patients with sinus rhythm,
and 5 beats for those with atrial fibrillation. Chamber diame-
ters, areas and volumes were normalized for body surface area.
Reproducibility of Doppler echocardiographic data (EDT
and EF) were assessed in 25 randomly selected study patients.
These measurements were repeated (mean of 3 beats) by the
same examiner (B.P.) and by another author (M.Z.), who were
unaware of the initial measurements. Intraobserver and inter-
observer variabilities (mean 6 SD) were 0 6 22.6 ms and 8 6
13.6 ms for EDT and 0.07 6 3.3% and 0.02 6 4.0% for EF,
respectively. In addition, we tested for a intrarater and inter-
rater variability using a linear random effect model. According
to the model, no rater effect exists (p 5 0.61), and the
observations are consistent across measurements (p 5 0.74).
Classification of patients. According to the Doppler LV
filling pattern at baseline and at short-term follow-up, the
patients were classified into three groups: Group 1A had
persistent RFP (EDT ,115 ms both at presentation and at
3-month follow-up); Group 1B had reversible RFP (EDT
,115 ms at presentation and .115 ms at 3-month follow-up);
and Group 2 had non-RFP (EDT .115 ms both at presenta-
tion and at 3-month follow-up).
Analysis of follow-up data. The follow-up data were ob-
tained by regular follow-up visits at our institution. Additional
information on survival was collected by telephone contact
with patients or their relatives and physicians.
Primary end points for follow-up were cardiac death or
heart transplantation, or at the end of the study. For the
purpose of analysis, patients who died or underwent cardiac
transplantation were considered as a single group.
A secondary objective was the assessment of clinical im-
provement at 1- and 2-year follow-up. Clinical improvement
was arbitrarily considered to be present in case of normaliza-
tion of LV function (EF .52%) in asymptomatic patients
(functional class I) or of an EF increase .10%, in association
with at least two of the following criteria: decrease of at least
one functional class;.10% decrease of cardiothoracic ratio on
chest x-ray film; .10% decrease of LV end-diastolic diameter
on M-mode echocardiography; or .120 s increase in exercise
time on effort test.
Statistical analysis. See Appendix for more detailed infor-
mation. Given the small number of cases with missing values in
one or more covariates (maximum 8%), and to avoid a possible
bias due to discarding patients, the data were imputed using a
psychometric scaling method (16). Main descriptive statistics
were computed for each group. Differences between group
means were compared using the unpaired Student t test, and
frequency of events using the chi-square test with the Yates
correction, where applicable. Longitudinal analyses within the
same group were performed using paired t tests and the
McNemar test. Bonferroni correction was applied for multiple
analyses. The survival curves were estimated using the Kaplan-
Meier approach. Confidence bounds were constructed using
Greenwood’s formula. To compare the patients of Group 1A
with those of Group 1B, a paired t test was performed on the
ranks of the Kaplan-Meier estimated survival times. To com-
pare the prognostic significance of RFP at baseline with the
persistence of RFP at 3 months, diagnostic accuracy in pre-
dicting mortality and heart transplantation, sensitivity, speci-
ficity, positive and negative test values, confidence bounds and
standard errors was constructed using a bootstrap approach
(17). To give a first indication of the effect of the covariates on
survival, the unadjusted relative risks were estimated. To
evaluate the impact of EDT after adjusting for the effect of
other covariates, we used the model presented in the previous
report by Pinamonti et al. (5), in which a Cox proportional
hazards model was employed (18); the covariates were consid-
ered in both the original (continuous) and the categorized
scale (for the cutoff points, refer to Table 3). In both models,
the two covariates that were inserted in the previous model
mainly for model stability (i.e., age and functional class) did
not turn out to be significant in our data at a Wald and a score
tests. Thus, we decided to drop them. Then, a forward stepwise
analysis was performed to see if any other variable could
produce a significant improvement in the fit. Finally, we
decided to consider the categorized model for further analysis,
mainly because of its easier clinical interpretation. The fact
that the two fitted models were basically the same, and that the
estimated effect of covariates did not change when categorizing
the variables, was a strong suggestion that no improper over-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
DCM5 dilated cardiomyopathy
E/A 5 ratio of early transmitral flow velocity
to atrial flow velocity
EDT 5 E wave deceleration time
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605JACC Vol. 29, No. 3 PINAMONTI ET AL.
March 1, 1997:604–12 RESTRICTIVE FILLING IN DILATED CARDIOMYOPATHY
estimation of the true effect of the covariates occurred
because of ad hoc cutting off. In comparing the baseline
model with the 3-month model to assess their predictive
power, the prediction error was estimated using the boot-
strap approach (19). The overall effect of EDT was assessed
using a proportional hazards model with EDT as time-
dependent covariate.
Results
Study group characteristics at presentation (Table 1). An
RFP was observed at presentation in 53 (48%) of 110 patients.
Similar to the results of the previous study (5), their clinical
data and hemodynamic status were more severe than in
patients without an RFP (Table 1).
After initial assessment, treatment with ACE inhibitors or
beta-blockers, or both, was started or tailored according to
clinical status up to the maximal tolerated dosage. At 3
months, 94% of patients were taking ACE inhibitors and 87%
beta-blockers (metoprolol 110 6 58 mg/day).
Short-term follow-up. The first follow-up echocardio-
graphic data—3 6 2 months after presentation (mean 111 6
54 days)—were available in all patients.
An RFP persisted in 24 patients classified in Group 1A (Fig.
1, upper tracings), whereas it disappeared in the other 29
patients classified in Group 1B (Fig. 1, lower tracings). At the
initial evaluation these two groups were similar with regards to
the majority of clinical, echocardiographic and hemodynamic
variables (Table 1). The only statistically significant differences
were age (Group 1A: 32 6 18 years; Group 1B: 43 6 11 years;
p 5 0.03) and history of mild (,170/100 mm Hg) hypertension
(4% in Group 1A vs. 31% in Group 1B; p 5 0.02).
After 3 6 2 months, a significant improvement in most
clinical and Doppler echocardiographic variables was observed
in the whole group of patients with DCM, particularly evident
in Groups 1B and 2 (Fig. 2). Notably, Group 1B patients could
tolerate a higher beta-blocker dosage (Table 1) (120 6 68 vs.
93 6 46 mg/day; p 5 0.0009).
Long-term follow-up—analysis of improvement. Ac-
cording to the aforementioned criteria, 39 patients (35%) were
considered improved at 1-year and 48 (44%) at 2-year follow-
up.
An RFP persisted for 1 and 2 years in the majority of Group
1A patients who survived until the controls (10 of 15 patients
at 1 year and 7 of 12 patients at 2 years, respectively). In
contrast, an RFP was not present in any of the patients of
Groups 1B and 2.
Considering the three groups of patients, improvement was
Table 1. Patient Characteristics
Group 1A Group 1A vs. Group 1B Group 1B Groups 1A and 1B vs. Group 2 Group 2 All Patients
Clinical data
Age (yr) 32 6 18.5 * 42.86 10.7 † 43 6 12 40.4 6 14.1
HT hist. (%) 4 * 31 * 27 23
NYHA III/IV (%) 54 55 ‡ 13 34
SBP (mm Hg) 110 6 14 117 6 12 ‡ 123 6 12 119 6 14
S3 (%) 81 86 ‡ 35 59
CTR 0.58 6 0.05 0.57 6 0.07 ‡ 0.52 6 0.06 0.55 6 0.07
Echocardiographic data
LVEDDI (cm/m2) 4.1 6 0.8 4 6 0.5 † 3.7 6 0.4 3.9 6 0.6
LAAI (cm2/m2) 18.3 6 6.2 18 6 5 ‡ 12 6 4 14.9 6 5.5
LVEDVI (ml/m2) 133 6 43 131 6 39 † 107 6 31 119.5 6 38
LVEF (%) 25 6 7 24 6 7 † 30 6 8 27.3 6 7.8
RVASF (%) 29 6 17.5 33 6 18 ‡ 50 6 14 41.1 6 18.9
EDT (ms) 86 6 24 85 6 17 ‡ 185 6 50 134.9 6 62.7
E (m/s) 0.8 6 0.2 0.9 6 0.2 ‡ 0.5 6 0.2 0.7 6 0.3
E/A 3.1 6 1.7 3.1 6 1.6 ‡ 1 6 0.5 2.1 6 1.6
MR .1/4 (%) 58 83 ‡ 24 47
Hemodynamic data
Mean AoP (mm Hg) 766 14 84 6 9 ‡ 89 6 10 84.2 6 12.1
CI (ml/min per m2) 3,158 6 1,117 3,348 6 978 ‡ 4,163 6 972 3,706 6 1,110
Mean PAWP (mm Hg) 196 8 17 6 10 ‡ 9 6 5 13.7 6 8.5
Therapy (after 3 mo)
ACE-I (%) 92 97 93 94
BB (%) 69 90 95 87
BB dosage (mg/day) 93 6 46 ‡ 1356 27 133 6 44 110 6 58
*p, 0.05. †p, 0.01. ‡p, 0.001. Data are presented as mean value 6 SD or percent of patients. ACE-I 5 angiotensin-converting enzyme inhibitors; AoP 5 aortic
pressure; BB 5 beta-blocker; CI 5 cardiac index; CTR 5 cardiothoracic ratio; E 5 peak velocity of E wave; E/A 5 ratio of early transmitral flow velocity to atrial
flow velocity; EDT 5 E wave deceleration time; HT hist. 5 history of hypertension (.140/90, ,170/100 mm Hg); LAAI 5 left atrial area index; LVEDDI 5 left
ventricular end-diastolic diameter index; LVEDVI 5 left ventricular end-diastolic volume index; LVEF 5 left ventricular ejection fraction; MR 5 mitral regurgitation;
NYHA 5 New York Heart Association functional class; PAPW 5 pulmonary artery wedge pressure; RVASF 5 right ventricular areas shortening fraction; S3 5 third
heart sound; SBP 5 systolic blood pressure.
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significantly more common in Group 1B (46% at 1 year and
67% at 2 years) and in Group 2 (40% at 1 year and 55% at 2
years) than in Group 1A (12% at 1 year and 0% at 2 years)
(p 5 0.006 at 1 year and p , 0.0001 at 2 years).
Figure 2 shows the evolution during long-term follow-up of
functional class, LV end-diastolic diameter index, EF and EDT
in the three groups of patients. Significant differences in these
variables versus those at baseline were present at 1 year and 2
years in Groups 1B and 2, but not in Group 1A.
Long-term follow-up—analysis of survival. In April 1995,
the mean follow-up duration was 40.7 6 20.2 months. No
patient was lost to follow-up; two died of noncardiac causes.
Twenty-six patients (24%) died of a cardiac cause (13 patients:
sudden death in 10 and heart failure in 3) or underwent cardiac
transplantation (13 patients) 25.5 6 19.6 months after presen-
tation.
Figure 3 shows the Kaplan-Meier survival curves (free from
death and heart transplantation) of the three groups of pa-
tients. After 1, 2 and 4 years, survival of patients with persistent
RFP (Group 1A: 65%, 46% and 13%, respectively) was
significantly lower (p , 0.0001) than that of the other two
groups (Group 1B: 100% at 1 and 2 years and 96% at 4 years;
Group 2: 100% at 1 and 2 years and 97% at 4 years). All but
1 of the 16 patients who died (3 patients) or underwent heart
transplantation (12 patients) for refractory heart failure be-
longed to Group 1A, as well as 6 of the 10 patients who had a
sudden death.
Table 2 compares sensitivity, specificity, predictive positive
and negative values and accuracy in predicting cardiac mortal-
ity and heart transplantation between the RFP present at
diagnosis and the persistence of RFP after 3 months of tailored
medical therapy. The presence of RFP at first evaluation
showed a good sensitivity, whereas the persistence of RFP was
significantly more specific and accurate.
On univariate Cox analysis, several variables, both at base-
line and at 3 months, significantly correlated with survival free
from heart transplantation (Table 3).
The EDT taken as a time-dependent covariate showed a
very highly significant value (odds ratio 0.12, p, 0.0001, Table
4). Table 4 shows the two Cox proportional hazards models
Figure 1. Examples of subsequent transmitral Doppler curves in a
patient fromGroup 1A (upper tracings)with a persistent restrictive filling
pattern and a patient from Group 1B (lower tracings) with a reversible
restrictive filling pattern. The curves at left were obtained at the first
examination and those at right after 3 months of treatment. E 5 E wave;
A 5 A wave; EDT 5 deceleration time of E wave. The arrows show the
beginning and the end of the E wave to measure the EDT.
Figure 2. Evolution of New York
Heart Association (NYHA) func-
tional class, left ventricular end-
diastolic diameter index (LVEDDI),
left ventricular ejection fraction
(LVEF) and E wave deceleration
time (EDT) in the patients of the
three groups. During follow-up, sig-
nificant improvement of functional
class and ejection fraction was ob-
served in Groups 1B and 2, associ-
ated with a decrease in left ventric-
ular end-diastolic diameter index
and prolongation of E wave deceler-
ation time. In contrast, no significant
variation of these variables was ob-
served in Group 1A with a persistent
restrictive filling pattern at 3 months.
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(multivariate analysis) that considered the EDT at baseline
and at 3 months, respectively. As mentioned in statistical
analysis section earlier, this model was derived from the
previous model (5), which was simplified by dropping the two
variables inserted for model stability (i.e., age and functional
class). In addition, on forward stepwise analysis, the only other
variable that showed a significant improvement in the model
(p 5 0.043) on the Wald test was the fractional shortening of
right ventricular areas. However, this variable was highly
correlated to EDT (5) and nonsignificant on a score test. The
respective predictive powers of the model incorporating EDT
at baseline (M1) and at 3 months (M2), estimated using the
bootstrap approach (17,20), showed a significant improvement
of M2 with respect to M1 (95th percentile of theta 5 22.655,
p 5 0.0039) (Table 4).
Discussion
Evolution of left ventricular filling in dilated cardiomyop-
athy. Previous work has demonstrated the importance of the
assessment of diastolic function and LV filling in patients with
DCM. Although this disease is mainly characterized by systolic
dysfunction, abnormalities in diastolic function were also re-
ported. In fact, earlier hemodynamic studies demonstrated
both an impairment of relaxation and an increase in chamber
stiffness (20). Furthermore, from a clinical standpoint, in
patients with heart failure, dyspnea and functional impairment
mainly depend on an increase of LV filling pressure (21),
whereas exercise intolerance is more related to diastolic than
systolic dysfunction (22). These data were confirmed more
recently by several studies using Doppler echocardiography.
Appleton et al. (1) defined the RFP of the transmitral Doppler
curve, characterized by a shortened EDT and frequently by a
predominant E wave. The RFP can be considered a useful
noninvasive sign of increased LV stiffness, as recently con-
firmed by experimental data (23,24). The present study con-
firms previous investigations that showed that the RFP is
common in DCM (3–5,7,9–11), particularly in patients with
more severe clinical and hemodynamic abnormalities (3–5,7,9–
12), and must be considered a powerful independent adverse
prognostic factor (5,9–11). Similar data were obtained by other
investigators in patients with “dilated myocardial disease” (6)
and with heart failure of various causes (8).
Some workers (7,9,11,13,14) found significant changes in
LV filling patterns during the course of different heart dis-
eases. Klein et al. (13) observed in serial echocardiographic
studies of patients with cardiac amyloidosis the frequent
appearance of a RFP that was correlated with an adverse
prognosis. In experimental works a progressive decrease of the
EDT with the appearance of a RFP was observed during the
development of heart failure (23,25).
A significant relation between LV filling patterns and the
clinical course of DCM was noticed by Werner et al. (7): A
filling pattern with a predominant E wave (presumably restric-
Figure 3. Survival curves—free
from heart transplantation—of the
three groups of patients with dilated
cardiomyopathy. Mortality plus heart
transplantation was significantly
higher in Group 1A, with a persis-
tent restrictive filling pattern, than
in the Groups 1B and 2. The num-
bers below the graph represent the
patients at risk for the three groups.
Table 2. Comparison Between Restrictive Filling Pattern at Baseline
and After 3 Months of Treatment in Predicting Mortality and
Heart Transplantation
RFP at
Baseline
RFP at
3 Months
p
Value
Sensitivity 0.79 0.72 0.72
Specificity 0.69 0.94 , 0.0001
Positive predictive value 0.43 0.81 0.001
Negative predictive value 0.89 0.9 0.97
Accuracy 0.67 0.88 0.001
RFP 5 restrictive filling pattern (E wave deceleration ,115 ms).
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tive) was more frequent in patients symptomatic for heart
failure than in stable patients with a longer duration of the
disease. Moreover, during follow-up, an increase in the A wave
velocity and a decrease in the E wave and E/A ratio were noted
in patients who showed clinical improvement, whereas oppo-
site changes were present in those patients who deteriorated.
Similar data were described by Shen et al. (9), associated with
a prolongation of the EDT.
Our data confirm these preliminary observations and give
additional information on the evolution of LV filling in pa-
tients with DCM. After 3 6 2 months of treatment with
vasodilators, digitalis and diuretics, frequently associated with
beta-blockers, the RFP disappeared in 53% of patients. This
evolution was associated with clinical improvement of heart
failure and frequently with an increase of the EF (Fig. 2).
Prognostic significance of evolution of filling. The present
study demonstrates that the evolution of LV filling pattern at
short-term follow-up is very helpful from a prognostic point of
view. In fact, the patients with RFP at diagnosis—with a bad
prognosis according to our previous results (5)—can be further
classified into two subgroups with different outcomes: Group
1A, in which RFP persisted, with a very high mortality and
transplantation rate (35% at 1 year, 54% at 2 years and 87% at
4 years); and Group 1B, with reversible RFP, with an excellent
long-term survival (96% at 4 years), comparable to that of
patients without RFP at diagnosis (Group 2: 97% at 4 years)
(Fig. 3). The presence of RFP after 3 months of treatment was
more specific (94%) and accurate (90%) in predicting mortal-
ity and heart transplantation in comparison to the presence of
RFP at first evaluation (62% and 67%, respectively), whereas
both study points had a good sensitivity (77% and 81%,
respectively) (Table 2). Moreover, on multivariate analysis, the
model incorporating the EDT at 3 months showed a signifi-
cantly higher predictive value with respect to this variable at
baseline (Table 4).
Proposed mechanisms. The reasons for the different evo-
lutions of LV filling among patients with DCM are complex,
and presumably caused by different mechanisms, such as the
heterogeneity of the structural and functional characteristics of
the disease and probably the effects of treatment. In our study
no data at initial evaluation could predict the subsequent
evolution of LV filling. The only two differences that were
statistically significant were age (younger in Group 1A) and a
history of mild hypertension (more frequent in Group 1B).
Several studies demonstrated that LV filling is load dependent.
In fact, a decrease in preload decreases the E velocity and E/A
ratio and probably prolongs the EDT, whereas an increase in
afterload prolongs relaxation (26–31). Severity of MR also
may influence LV filling (2), probably acting on filling pres-
sure.
Thus, the Doppler mitral curve changes in some of our
patients may be due at least in part to drug treatment of heart
failure, which influenced preload (29), afterload, MR (30) and
presumably also ventricular interaction and pericardial re-
straint (32). Furthermore, a favorable action on the diastolic
transmitral Doppler curves may be due to treatment with
beta-blockers (33,34). Very recently, Andersson et al. (34)
demonstrated that in patients treated with metoprolol, the
maximal effects on diastolic variables were reached during the
first 3 months of treatment, whereas improvement in the systolic
function was observed later.
Although the present study was not specifically designed to
assess the influence of beta-blockers on diastolic function and
prognosis, and treatment with these drugs was not randomly
assigned, it must be noted that the majority of our patients
were treated with beta-blockers (Table 1), and that patients
Table 3. Cox Regression Models for Survival: Univariate Analysis
Covariate Cutoff Value Beta RR (95% CI) E (beta) p Value
Baseline
PAWP (mm Hg) .17 1.36 3.91 (1.88–8.13) 0.373 0.00026
EDT (ms) .115 21.6 0.201 (0.0819–0.495) 0.459 0.00048
RVASF (%) .35 21.2 0.3 (0.142–0.636) 0.383 0.0017
LAAI (cm2/m2) .15 1.2 3.31 (1.47–7.47) 0.416 0.004
CI (liters/min per m2) .2.5 21.01 0.364 (0.169–0.784) 0.391 0.0098
Mean AoP (mm Hg) .80 20.909 0.403 (0.194–0.836) 0.372 0.015
NYHA III–IV vs. I–II 0.897 2.45 (1.18–5.09) 0.372 0.016
LVEDVI (ml/m2) .120 0.729 2.07 (0.989–4.34) 0.377 0.053
Age (yr) .40 20.649 0.522 (0.25–1.09) 0.376 0.084
LVEF (%) .25 20.259 0.772 (0.448–1.33) 0.277 0.35
3 Months
EDT (ms) .115 22.93 0.0537 (0.0232–0.124) 0.427 , 0.0001
RVASF (%) .35 21.96 0.141 (0.0665–0.3) 0.385 , 0.0001
LAAI (cm2/m2) .15 1.95 7.03 (3.11–15.9) 0.416 , 0.0001
LVEF (%) .25 20.872 0.418 (0.26–0.673) 0.243 0.00033
BB dosage* 20.00995 0.99 (0.985–0.996) 0.00287 0.00053
NYHA III–IV vs. I–II 1.26 3.52 (1.6–7.75) 0.403 0.0018
LVEDVI (ml/m2) .120 0.751 2.12 (1.02–4.39) 0.372 0.044
*Continuous variable. CI 5 confidence interval; RR 5 risk ratio. Other abbreviations as in Table 1.
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with reversible RFP (Group 1B) could tolerate higher doses of
beta-blockers than those with persistent RFP (Group 1A).
These observations appear to be in agreement with those of
Bristow et al. (35), who demonstrated that in patients with
heart failure the functional improvement due to beta-blocker
treatment appears to be dose related. Nevertheless, because
our patients were not randomized but titrated to the maximal
tolerated dose, we cannot exclude that those receiving a higher
dose of beta-blockers were the same who had the best prog-
nosis.
Unfortunately, in Group 1A patients the RFP persisted
despite tailored drug treatment. Presumably in these patients
the disease was more severe or progressive. As suggested by
Bortone et al. (36), more severe structural myocardial abnor-
malities, such as fibrosis, were hypothesized. Further studies
using morphometric analysis of endomyocardial biopsy are
necessary to answer this question (37).
Study limitations. This study has several potential limita-
tions. First, the number of patients with persistent RFP was
quite small. Because hemodynamic study was not repeated
systematically after 3 months, we cannot know whether persis-
tent RFP was related to a persistent increase in LV filling
pressure, and which one was the best prognostic factor.
In DCM the evolution of the left ventricle during the course
of the disease is presently unknown. We arbitrarily considered
the changes in the LV filling pattern at a mean interval of 3
months after the first evaluation. Further studies may be
helpful to identify the optimal interval for the evaluation of the
response to treatment on LV filling. Moreover, because DCM
is probably a heterogeneous disease, different evolutions could
be expected among different patients. In our series the persis-
tence of RFP was a valuable predictor of refractory heart
failure, leading frequently to cardiac transplantation or death
(15 of 16 patients). However, sudden death is also a major
problem in patients with DCM, and it was confirmed in our
patients. Although the risk of sudden death appears to be
related to the severity of ventricular arrhythmias (38) and
systolic dysfunction (39), it is uncertain whether the presence
of RFP could also have a prognostic role. Finally, diastole is a
complex phenomenon that is difficult to analyze from any
single variable. Recent data showed that the evaluation of
pulmonary venous Doppler curves gives additional informa-
tion on LV diastolic pressures (40). Systematic analysis of
these curves was not performed in this study.
Clinical implications. Our study demonstrates that in pa-
tients with DCM the Doppler echocardiographic assessment of
the evolution of LV filling during tailored medical therapy is
clinically helpful in predicting subsequent prognosis and it
might be used in conjunction with the clinical assessment to
Table 4. Multivariate Analysis
Overall Model (Time-Dependent Covariate)
Coef. SE (Coef.) OR p Value
EDT 22.04 0.308 0.129 , 0.001
Likelihood ratio test 5 54.3 on 1 df, p 5 1.74e2013.
Baseline Model—Categorized Variables (M1)
Coef. OR Lower Bound (OR) Upper Bound (OR) p Value
EDT 21.039 0.354 0.131 0.957 0.041
Mean PAWP 1.056 2.875 1.284 6.435 0.01
Mean AoP 20.805 0.447 0.208 0.962 0.039
r2 5 0.2 (max. possible 0.894).
3-Month Model—Categorized Variables (M2)
Coef. OR Lower Bound (OR) Upper Bound (OR) p Value
EDT 22.074 0.066 0.0226 0.169 , 0.001
Mean PAWP 0.346 1.413 0.6271 3.188 0.058
Mean AoP 20.363 0.695 0.3253 1.488 0.06
r2 5 0.393 (max. possible 0.894).
Models
Comparison Between M1 and M2
95th Percentile of Theta p Value
M2 vs. M1 22.655 0.0039
For cutoff values for significant categorized variables, see Table 3. Coef. 5 correlation coefficient; df 5 degrees of freedom; max. 5 maximum; OR 5 odds ratio;
other abbreviations as in Table 1.
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select patients for a more strict follow-up or for cardiac
transplantation.
From the present study the structural substrate of persistent
RFP remains undefined and further studies are necessary to
elucidate this topic.
Appendix
Statistical Analysis
Group comparison. To derive test statistics for the hypothesis that the
sensitivity and specificity and other statistics are different if based on the baseline
EDT or the 3-month EDT, we used a bootstrap approach (17).
Let (x1i, y1i, x2i, y2i) be a vector of the observations for the ith subject, where
x1 refers to the baseline EDT, y1 to the baseline outcome (dead/alive) and the
same for y2, but for the EDT at 3 months. We are interested in the statistics: u 5
uBase 2 u3m, to test the null hypothesis that u 5 0.
If n is the number of observations, then we can decide to extract the B
bootstrap sample from X 5 $~x1i
j1, y1i
j1, x2i
j1, y2i
j1!, . . ., ~x1i
jn, y1i
jn, x2i
jn, y2i
jn!% for j1,
. . . , jn a random sample of integers from 1 to n.
Then, the bootstrap estimate is uˆb
* 5 uˆBaseb
* 2 uˆ3mb
* where uˆ 5 (b21B ub* /B
with b 5 1, . . . , B, and
SE*5 HOb21B ~uˆ*b 2 uˆ*!2B2 1 J
1/2
.
Then a test and a confidence bound can be derived using the normal
approximation:
u e uˆ*6 z~12a!SE*,
where SE represents standard error, and z represents normal (1 2 a).
The asymptotic normality of the bootstrap estimate has been checked using
quantile–quantile (QQ) plots.
Predictive value of EDT at baseline and 3 months. To address whether the
EDT at 3 months has a higher discriminant predictive power than the EDT at
baseline, after adjusting for the relevant confounding effects, we used an
approach introduced by Efron and Tibshirani (19), which allows comparisons in
terms of accuracy of predictions between two different models.
Let us call the two models we are interested in M1 and M2, where M1 is the
baseline model and M2 is the model for the 3-month EDT, both adjusted for the
baseline pulmonary wedge pressure and mean aortic pressure (see Results and
Table 4). Using the same idea as outlined earlier, a formal comparison can be
based on the statistics for the generic jth model (j 5 1, 2):
RSE~Mj! 5 O
i51
n
~yi 2 yˆ~Mj!!2
(where RSE represents residual square error), which indicates good prediction
for small values and a perfect fit in correspondence with the 0. Thus, M1 and M2
were compared with respect to their predictive power, by comparing RSE(M1)
and RSE(M2).
A statistic like uˆ can then be introduced to compare the two previous
statistics:
uˆ 5
1
n @RSE~M2! 2RSE~M3!#.
A positive value of uˆ would indicate that the M1 model is not as good as the
M2 model for predicting long-term survival.
We used the bootstrap BC or ABC methods to derive the confidence bounds
of u. For details refer to Efron and Tibshirani (19). The models M1 and M2 are
proportional hazards regressions, and RSE is the deviance residual for them.
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